View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...

 PRESS RELEASE

American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 F...

American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 Financial Results SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “company”) today reported financial results for its fourth quarter and year ended December 31, 2025. Fourth Quarter Highlights Net income available to common stockholders of $3.1 million and $55.6 million for the three months and year ended December 31, 2025, respectively, or $0.05 and $0.92 per diluted share, respectively.FFO of $0.47 and $2.00 per diluted share for the three months and year ended December 3...

 PRESS RELEASE

Standard BioTools Completes Sale of SomaLogic to Illumina

Standard BioTools Completes Sale of SomaLogic to Illumina Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy  Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announ...

 PRESS RELEASE

American Assets Trust, Inc. Releases Tax Status of 2025 Distributions

American Assets Trust, Inc. Releases Tax Status of 2025 Distributions SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the tax treatment of its 2025 dividend distributions as follows: Security Descriptions: Common StockCUSIP: 024013104Ticker Symbol: AAT Record DatePayable DateTotal Distribution Per ShareAllocable to 2025Taxable Ordinary DividendLT Capital GainUnrecaptured Sec. 1250 GainSection 199A DividendsReturn of Capital03/06/2503/20/25$0.340$0.340$0.140480$0.059651$0.042897$0.140480$0.13986906/05/2506/19/25$0.340$0....

 PRESS RELEASE

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025...

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2025 earnings in a press release to be issued after the market closes on Tuesday, February 3, 2026. Senior management will hold a conference call for its fourth quarter and year-end 2025 earnings on Wednesday, February 4, 2026 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 a...

 PRESS RELEASE

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2...

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuin...

 PRESS RELEASE

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare C...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...

Dollar Tree, Inc. - November 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 26, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Opko Health Inc: 1 director

A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Marriott Vacations Worldwide Corp: 1 director

A director at Marriott Vacations Worldwide Corp bought 5,000 shares at 48.080USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch